EVGN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.240

Open

1.200

VWAP

1.10

Vol

12.85M

Mkt Cap

9.26M

Low

0.980

Amount

14.18M

EV/EBITDA(TTM)

--

Total Shares

8.72M

EV

11.74M

EV/OCF(TTM)

--

P/S(TTM)

0.96

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Show More

Events Timeline

(ET)

2026-02-04

08:10:00

Evogene and Shanghai Lishan Biopharmaceuticals Sign Exclusive Licensing Agreement for BMC128

2026-01-07 (ET)

2026-01-07

07:20:00

Evogene Partners with Unravel Biosciences to Develop Neurological Disease Therapy

2025-12-30 (ET)

2025-12-30

07:10:00

Evogene Appoints Dr. Olga Nissan as VP of Business Development

2025-11-11 (ET)

2025-11-11

07:05:33

Evogene's Casterra and Fantini Reveal Strategic Partnership

2025-08-22 (ET)

2025-08-22

05:52:22

Evogene announces Q2 earnings per share of 10 cents, compared to a loss of 5 cents last year.

2025-08-19 (ET)

2025-08-19

07:06:04

Evogene announces Q2 continuing operations EPS of 50 cents compared to a loss of 85 cents last year.

2025-06-10 (ET)

2025-06-10

07:11:52

Evogene announces completion of generative AI foundation model with Google Cloud

2025-05-21 (ET)

2025-05-21

07:04:42

Evogene reports Q1 EPS (38c) vs. (76c) last year

News

an image of Globenewswire

03:47 AMGlobenewswire

Evogene and Lishan Biotech Sign Exclusive Licensing Agreement

an image of Newsfilter

01-16Newsfilter

EverGen Infrastructure Closes $13M Financing to Enhance Financial Flexibility

an image of Yahoo Finance

01-16Yahoo Finance

EverGen Infrastructure Closes $13M Financing to Optimize Debt Structure

an image of Businesswire

01-16Businesswire

EverGen Infrastructure Closes $13M Financing, Restructures Debt

an image of Yahoo Finance

01-13Yahoo Finance

EverGen Infrastructure Updates: $13M Debt Refinancing and $2M Private Placement

an image of Businesswire

01-13Businesswire

EverGen Infrastructure Corp. Updates on $13M Debt Refinancing and $2M Private Placement

1 Analyst Rating

Wall Street analysts forecast EVGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVGN is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Alliance Global Partners

Scott Henry

Buy

downgrade

$6

AI Analysis

2025-06-06

Reason

Alliance Global Partners

Scott Henry

Price Target

$6

AI Analysis

2025-06-06

downgrade

Buy

Reason

Alliance Global Partners analyst Scott Henry lowered the firm's price target on Evogene to $3.50 from $6 and keeps a Buy rating on the shares, citing lower forecasts and potentially higher equity dilution after the company reported Q1 earnings that featured a revenue shortfall offset by cost cuts. The Lavie Bio sale should fortify the balance sheet, although at a lower price than expected, and Casterra castor seed revenue continues to trail the firm's forecasts, the analyst noted.

Lake Street

Ben Klieve

Buy

downgrade

$5

2025-05-22

Reason

Lake Street

Ben Klieve

Price Target

$5

2025-05-22

downgrade

Buy

Reason

Lake Street analyst Ben Klieve lowered the firm's price target on Evogene to $3.50 from $5 and keeps a Buy rating on the shares. Mixed Q1 results were highlighted by an extended cash runway via a Lavie Bio asset sale and strong year-over-year growth out of Casterra, the analyst tells investors. The number of potential catalysts is declining, but a major potential event of a follow on seed order and/or commercial castor oil agreement "represent the major potential events in 2025," the analyst says. The firm maintains a Buy rating on Evogene, but adds that "our conviction has been on the decline for several quarters."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EVGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Evogene Ltd (EVGN.O) is -0.97, compared to its 5-year average forward P/E of -1.90. For a more detailed relative valuation and DCF analysis to assess Evogene Ltd 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-1.90

Current PE

-0.97

Overvalued PE

-0.07

Undervalued PE

-3.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-0.61

Current EV/EBITDA

-1.57

Overvalued EV/EBITDA

0.17

Undervalued EV/EBITDA

-1.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

36.38

Current PS

3.53

Overvalued PS

120.25

Undervalued PS

-47.48

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks between $1.00 and $1.10

Intellectia · 54 candidates

Price: $1.00 - $1.10

Ticker

Name

Market Cap$

Adagio Medical Holdings Inc

22.87M

Heidmar Maritime Holdings Corp

61.90M

CCSC Technology International Holdings Ltd

4.15M

Auddia Inc

3.35M

Estrella Immunopharma Inc

42.45M

CytoMed Therapeutics Ltd

11.15M

Whales Holding EVGN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Evogene Ltd (EVGN) stock price today?

The current price of EVGN is 1.09 USD — it has increased 4.81 % in the last trading day.

What is Evogene Ltd (EVGN)'s business?

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

What is the price predicton of EVGN Stock?

Wall Street analysts forecast EVGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVGN is2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Evogene Ltd (EVGN)'s revenue for the last quarter?

Evogene Ltd revenue for the last quarter amounts to 312.00K USD, decreased -82.07 % YoY.

What is Evogene Ltd (EVGN)'s earnings per share (EPS) for the last quarter?

Evogene Ltd. EPS for the last quarter amounts to 0.44 USD, decreased -133.59 % YoY.

How many employees does Evogene Ltd (EVGN). have?

Evogene Ltd (EVGN) has 117 emplpoyees as of February 05 2026.

What is Evogene Ltd (EVGN) market cap?

Today EVGN has the market capitalization of 9.26M USD.